BioInvent receives IND approval for Phase I/IIa trial of anti-TNFR2 antibody BI-1808

LUND, Sweden, April 7, 2021 /PRNewswire/ — BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) for the Phase I/IIa clinical study of the immuno-modulatory…

Continue Reading

HEDGE accordingly